Дьяконов, В.А.,
Джемилева, Л.У.,
Джемилев, У.М.,
D'yakonov, V.A.,
Dzhemileva, L.U.,
Dzhemilev, U.M. (2017) studies in this field have shown that
topoisomerases I and II are one of the main molecular targets
D’yakonov, Vladimir A.,
Dzhemileva, Lilya U.,
Makarov, Aleksey A.,
Mulyukova, Alfiya R.,
Baev, Dmitry S,
Khusnutdinova, Elza K,
Tolstikova, Tatiana G.,
Dzhemilev, Usein M. (2016) topoisomerase I and II
was studied. Resorting to the data of molecular docking, a
probable mechanism
Dzhemilev, Usein M.,
D’yakonov, Vladimir A.,
Tuktarova, Regina A.,
Dzhemileva, Lilya U.,
Ishmukhametova, Svetlana R.,
Yunusbaeva, Milyausha M.,
Armin de Meijere (2016) activity against
topoisomerases I and
IIα, key cell cycle enzymes. Using flow cytometry, muricadienin
Yagudin, T.,
Zhao, Y.,
Gao, H.,
Zhang, Y.,
Yang, Y.,
Zhang, X.,
Ma, W.,
Daba, T.M.,
Ishmetov, V.,
Kang, K.,
Yang, B.,
Pan, Z. (2020)
infarction in order to facilitate the development of
novel therapy.
Inhibitor of apoptosis
on the activity of hydrolytic enzymes (amylases and proteinases) and their protein
inhibitors in the leaves
Asadullina, D.D.,
Gilyazova, I.R.,
Ivanova, E.A.,
Izmailova, S.M.,
Gilyazova, G.R.,
Pavlov, V.N.,
Khusnutdinova, E.K. (2024) inhibitors (ICI) still have limited therapeutic efficacy. A growing number of investigations has demonstrated